高危乳腺癌改良根治术后大分割对比常规分割放疗:CHN HYPOPMRT 3期试验10年结局
BACKGROUND: Hypofractionated radiotherapy is an established alternative to conventional fractionation for breast cancer, but long-term evidence after mastectomy with regional nodal irradiation is scarce.…
要点
- 10年3级不良事件两组均少见,未发生4-5级事件、臂丛神经病或治疗相关死亡。
- 大分割方案3周完成,较常规5周更省时,支持其作为替代选择。
核心结论
- 高危乳腺癌改良根治术后大分割放疗提供持久的局部区域控制,与常规分割相比未增加严重晚期不良事件,支持其作为更省时的选择。
研究设计与样本
- 随机、非劣效、开放标签3期试验在中国国家癌症中心开展,820例高危乳腺癌改良根治术后患者1:1随机分配至常规分割放疗(414例)或大分割放疗(406例)。
- 主要终点为5年局部区域累积复发率,非劣效界值5%;本次为预设长期分析,报告10年结局,未额外进行非劣效验证。
主要发现
- 10年最常见的3级不良事件为缺血性心脏病(常规分割5/409例[1%] vs 大分割5/401例[1%])和淋巴水肿(4/409例[1%] vs 3/401例[<1%])。
- 10年3级肩关节功能障碍(2/409例[<1%] vs 1/401例[<1%])和皮肤不良事件(0例 vs 1/401例[<1%])均少见。
- 未发生4-5级事件、臂丛神经病、严重不良事件或治疗相关死亡。
关键数值与推荐
- 入组条件:18-75岁女性,高危乳腺癌,已行改良根治术和腋窝淋巴结清扫,Karnofsky体能评分≥60%。
- 非劣效界值为5%,主要终点为5年局部区域累积复发率。
临床怎么用
- 大分割方案未增加严重晚期不良事件,长期安全性数据支持其临床使用。
局限性
- 本研究为开放标签设计,未设盲。
- 全部患者为女性,未收集种族和族裔数据。
- 10年分析为预设长期分析,未额外进行非劣效性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypofractionated radiotherapy is an established alternative to conventional fractionation for breast cancer, but long-term evidence after mastectomy with regional nodal irradiation is scarce. We aimed to assess the long-term efficacy and adverse event profile of hypofractionated versus conventional fractionated postmastectomy radiotherapy in high-risk breast cancer. METHODS: This randomised, non-inferiority, open-label, phase 3 trial was done at a national cancer centre in China. Eligible patients were women aged 18-75 years with high-risk breast cancer who had undergone modified radical mastectomy and axillary dissection with a Karnofsky performance score 60% or higher. Participants were randomly assigned (1:1) to conventional fractionated radiotherapy (50 Gy in 25 fractions over 5 weeks) or hypofractionated radiotherapy (43·5 Gy in 15 fractions over 3 weeks) to the chest wall and supraclavicular region, using a computer-generated sequence with concealed allocation and no masking. The primary endpoint was 5-year cumulative incidence of locoregional recurrence, analysed in the modified intention-to-treat population (including all eligible patients who underwent randomisation, but excluding those who were considered ineligible or withdrew consent after randomisation) and a 5% margin was used to establish non-inferiority. In this prespecified long-term analysis, outcomes at 10 years were analysed without additional confirmatory non-inferiority testing. Safety was analysed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT00793962, and is closed to enrolment. FINDINGS: Between June 12, 2008, and June 16, 2016, 2157 patients were assessed for eligibility. 1337 were excluded and 820 patients were enrolled and randomly assigned (414 to conventional fractionated radiotherapy and 406 to hypofractionated radiotherapy). Five patients were excluded in each group and 810 were included in the analyses (409 to conventional fractionated radiotherapy and 401 to hypofractionated radiotherapy). Median follow-up was 11·5 years (IQR 9·6-13·8). Median patient age was 49 years (range 24-74), and 761 (94%) patients had stage III disease. All patients were female, and data on race and ethnicity were not collected. At 10 years, cumulative locoregional recurrence was 10·3% (95% CI 7·3-13·3) with conventional fractionated radiotherapy and 12·0% (8·8-15·2) with hypofractionated radiotherapy (hazard ratio 1·19, 95% CI 0·79-1·82). The most common grade 3 adverse events at 10 years were ischaemic heart disease (five [1%] of 409 patients in the conventional fractionated radiotherapy group vs five [1%] of 401 patients in the hypofractionated radiotherapy group), lymphoedema (four [1%] vs three [<1%]), shoulder dysfunction (two [<1%] vs one [<1%]), and skin adverse events (none vs one [<1%]). No grade 4-5 events, brachial plexopathy, serious adverse events, or treatment-related deaths occurred. INTERPRETATION: Hypofractionated postmastectomy radiotherapy provided durable locoregional control with no increase in severe late adverse events compared with conventional fractionation, supporting its use as a more time-efficient option than conventional fractionated radiotherapy. FUNDING: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, Cooperation Fund of CHCAMS, and CAMS Innovation Fund for Medical Sciences.
引用
- Sun GY, Chen SY, Tang Y, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2026. PMID: 42805199. doi:10.1016/S1470-2045(26)00297-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。